Sanofi shares top the CAC 40 and break through their 84.53 € resistance
The pharmaceutical company extends its sharp rebound of recent weeks in a Paris market trending higher. A very favorable analyst rating, published this Monday, accompanies the move and renews interest in the stock.
An intraday breakout that places Sanofi above its 150-session high
The stock gains 2.41% to 85.76 € and holds the first place in the CAC 40, in an index that rises 0.36%.
Intraday, it broke above its former resistance at 84.53 €, which now serves as its support, with an RSI at 80 signaling an overbought configuration. This move extends a series of gains: the stock is up 7.55% over one week and 20.91% over one month, after touching a multi-year low in early October.
For Sanofi shares, the next technical level is resistance at 89.89 €. The group had raised its 2026 targets on October 30, after a third quarter up 14.3% driven by Dupixent.
Exane BNP Paribas raises its price target to 102 € and moves to outperform
Exane BNP Paribas raised its price target from 79 € to 102 €, and its rating moved from neutral to outperform, implying upside potential of about 19% relative to the current share price. This move adds to the target increase by Barclays, which occurred in early November.
Based on expected earnings per share, according to the consensus of analysts surveyed, the stock trades at about 9.6 times current-year earnings and 9.2 times next-year earnings.
The analyst consensus will be watched in the coming days. On the technical side, the gap remains pronounced with moving averages: the price is 11.75% above the MM20 and 11.72% above the MM200.
